|
CMC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.16439999997553E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6272799999939E-05 |
| Normal-vs-Stage2 |
1.388850E-01 |
| Normal-vs-Stage3 |
8.77550000000227E-07 |
| Normal-vs-Stage4 |
1.40420000072083E-08 |
| Stage1-vs-Stage2 |
1.664420E-01 |
| Stage1-vs-Stage3 |
1.574800E-01 |
| Stage1-vs-Stage4 |
2.555300E-03 |
| Stage2-vs-Stage3 |
4.417600E-02 |
| Stage2-vs-Stage4 |
4.117100E-03 |
| Stage3-vs-Stage4 |
1.322770E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.45480000268705E-08 |
| Normal-vs-AfricanAmerican |
2.380200E-03 |
| Normal-vs-Asian |
5.78959999999462E-05 |
| Caucasian-vs-AfricanAmerican |
8.484200E-01 |
| Caucasian-vs-Asian |
7.973400E-01 |
| AfricanAmerican-vs-Asian |
9.979000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.25059999999777E-05 |
| Normal-vs-Female |
2.03629999995236E-06 |
| Male-vs-Female |
5.621800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.70640000000311E-05 |
| Normal-vs-Age(41-60Yrs) |
4.25420000005339E-07 |
| Normal-vs-Age(61-80Yrs) |
1.842090E-03 |
| Normal-vs-Age(81-100Yrs) |
5.241600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.176440E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.215400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.475800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.304400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.651000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.945200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.335100E-03 |
| Classical-VS-Follicular |
8.219300E-04 |
| Classical-VS-Other |
9.815000E-01 |
| Classical-VS-Normal |
1.88619997398831E-09 |
| Tall-VS-Follicular |
8.93930000023246E-07 |
| Tall-VS-Other |
1.393390E-01 |
| Tall-VS-Normal |
8.78599970555172E-10 |
| Follicular-VS-Other |
2.851000E-01 |
| Follicular-VS-Normal |
1.477160E-01 |
| Other-VS-Normal |
3.068400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.833800E-04 |
| Normal-vs-N1 |
5.4995999998475E-07 |
| N0-vs-N1 |
8.876200E-03 |
|
|
